TCL Archive NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA. July 13, 2007
TCL Archive Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events June 28, 2013
TCL Archive ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic. April 9, 2010